Digital twins of cancer patients predict effectiveness of treatments

FarrSight-Twin was presented on October 24, 2024 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

According to the researchers, this approach could be used by cancer researchers to run virtual clinical trials before testing new treatments on patients. It could also be used alongside clinical trials with a digital twin for each patient taking part, which together could form a control group for any trial. It might also mean that patients could have different treatments tested on their digital twin to help select the most suitable treatment ahead of time.

The research was presented by Dr Uzma Asghar, co-founder and chief scientific officer at Concr and a consultant medical oncologist.

“Around the world, we spend billions of dollars on developing new cancer treatments. Some will turn out to be successful, but most will not,” she said in a statement. “We can use digital twins to represent individual patients, build clinical trial cohorts and compare treatments to see if they are likely to be successful before testing them out with real patients.”